Q2 2019 EPS Estimates for AMAG Pharmaceuticals, Inc. (AMAG) Decreased by SunTrust Banks
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Equities research analysts at SunTrust Banks decreased their Q2 2019 earnings per share (EPS) estimates for AMAG Pharmaceuticals in a research report issued to clients and investors on Monday, May 13th. SunTrust Banks analyst G. Gilbert now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.82) for the quarter, down from their previous forecast of ($0.68). SunTrust Banks currently has a “Hold” rating and a $13.00 target price on the stock. SunTrust Banks also issued estimates for AMAG Pharmaceuticals’ Q3 2019 earnings at ($0.33) EPS, Q4 2019 earnings at ($1.18) EPS, FY2019 earnings at ($5.86) EPS, FY2020 earnings at ($3.67) EPS, FY2021 earnings at ($0.93) EPS, FY2022 earnings at $0.77 EPS and FY2023 earnings at $2.28 EPS.
Several other brokerages have also commented on AMAG. BidaskClub raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research lowered AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 20th. ValuEngine lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, February 27th. B. Riley set a $21.00 price objective on AMAG Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, January 16th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $14.00 price target (down previously from $17.00) on shares of AMAG Pharmaceuticals in a research report on Thursday, March 14th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $19.41.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.77). The company had revenue of $75.80 million during the quarter, compared to the consensus estimate of $90.13 million. AMAG Pharmaceuticals had a negative net margin of 30.90% and a negative return on equity of 26.33%. The business’s revenue was down 35.4% on a year-over-year basis. During the same quarter last year, the firm earned ($1.59) EPS.
In other news, CEO William K. Heiden purchased 10,000 shares of the business’s stock in a transaction on Thursday, May 9th. The stock was acquired at an average cost of $10.70 per share, for a total transaction of $107,000.00. Following the purchase, the chief executive officer now directly owns 490,056 shares in the company, valued at approximately $5,243,599.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Elizabeth Scott Bolgiano purchased 5,000 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were purchased at an average price of $10.93 per share, with a total value of $54,650.00. Following the completion of the purchase, the insider now owns 74,847 shares in the company, valued at $818,077.71. The disclosure for this purchase can be found here. Insiders own 4.90% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in AMAG. Pearl River Capital LLC bought a new stake in shares of AMAG Pharmaceuticals during the 4th quarter valued at about $28,000. NumerixS Investment Technologies Inc grew its position in AMAG Pharmaceuticals by 17.8% during the 1st quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 1,083 shares in the last quarter. Quantamental Technologies LLC purchased a new position in AMAG Pharmaceuticals during the 4th quarter worth approximately $107,000. First Quadrant L P CA purchased a new position in AMAG Pharmaceuticals during the 4th quarter worth approximately $141,000. Finally, Municipal Employees Retirement System of Michigan purchased a new position in AMAG Pharmaceuticals during the 4th quarter worth approximately $151,000.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Recommended Story: Back-End Load
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.